Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Melanoma cell adhesion molecule (MCAM), also widely known as CD146 or MUC18, is a transmembrane glycoprotein belonging to the immunoglobulin superfamily. It is primarily expressed on endothelial cells, smooth muscle cells, pericytes, and a subset of activated T lymphocytes, where it plays a critical role in cell-cell adhesion, endothelial junction cohesion, and vascular permeability. MCAM also functions as a signaling receptor, triggering intracellular cascades such as tyrosine phosphorylation of FYN and FAK1, which link cell surface adhesion to cytoskeletal rearrangement and cell migration.\n\nIn pathological states, MCAM is highly overexpressed in various solid tumors, including melanoma, osteosarcoma, and lung, breast, and ovarian cancers, where it promotes tumor angiogenesis, epithelial-mesenchymal transition (EMT), and metastatic dissemination. Consequently, MCAM has emerged as a promising therapeutic target in oncology and inflammatory diseases. Therapeutic strategies targeting MCAM include antibody-drug conjugates (ADCs) like AMT-253, which delivers a topoisomerase I inhibitor payload to tumor cells, and monoclonal antibodies like imaprelimab (PRX003) designed to block its pro-inflammatory and angiogenic signaling. Additionally, dual-targeting CAR-T cell therapies directed against MCAM are under clinical evaluation. However, because MCAM is also expressed on normal vasculature, managing on-target, off-tumor toxicities remains a key therapeutic challenge.
Antibody-drug conjugate targeting MUC18/CD146 to deliver a cytotoxic payload (exatecan) to tumor cells; monoclonal antibody blocking CD146-mediated cell adhesion and signaling; CAR-T cell therapy targeting CD146-expressing tumor cells
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Melanoma cell adhesion molecule (MCAM) (MCAM).